Course: Targeting the PI3K/AKT/PTEN Pathway for Treatment of Breast Cancer: Innovative Solutions for Equitable Care
CME Credits: 0.00
Released: 2024-12-13
The PI3K/AKT/PTEN pathway has emerged as a key player in breast cancer development. Notably, up to 50% of patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative (HR+/HER2-) breast cancer have actionable biomarkers within this pathway, paving the way for novel approaches to management. This CME/CE activity will cover emerging therapeutic strategies for HR+/HER2- breast cancer that target the PI3K/AKT/PTEN pathway as well as best practices for enhancing early detection and management of treatment-related adverse events. Experts will also discuss ways to improve adherence to therapy and care coordination among rural and underserved populations using a multidisciplinary approach. This enduring activity is a recorded session from Oncology Congress that took place on September 28, 2024.
Upon completion of this activity, participants should be better able to:
View Full Course